Flow-controlled Ventilation (FCV) in Moderate Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19

CompletedOBSERVATIONAL
Enrollment

11

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

April 23, 2021

Study Completion Date

May 1, 2021

Conditions
COVID-19 Acute Respiratory Distress SyndromeRespiration, Artificial
Interventions
DIAGNOSTIC_TEST

Arterial blood gas (ABG)

Arterial blood gasses will be drawn during baseline PCV, and every 15 minutes during FCV and VCV respectively. pO2 (mmHg), pCO2 (mmHg) and pH will be recorded.

OTHER

Recording of hemodynamic monitoring

Hemodynamic parameters (invasive arterial blood pressure (mmHg) and heart rate (beats per minute)) will be recorded every 5 minutes.

OTHER

Recording of respiratory monitoring

Tidal volume (ml), respiratory rate (breaths per minute), minute volume (l/min), dynamic compliance (ml/cmH2O), resistance (cmH2O/l/min), plateau pressure (cmH2O), mean airway pressure (cmH2O), positive end-expiratory pressure (cmH2O), peak inspiratory pressure (cmH2O) and fraction of inspired oxygen will be recorded every 5 minutes.

Trial Locations (1)

2650

Antwerp University Hospital, Edegem

All Listed Sponsors
lead

University Hospital, Antwerp

OTHER

NCT04894214 - Flow-controlled Ventilation (FCV) in Moderate Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 | Biotech Hunter | Biotech Hunter